- Q2 2024 Hansa Biopharma AB Earnings Call TranscriptJul 18, 2024kr38.8 (-16.67%)Earnings
- Q1 2024 Hansa Biopharma AB Earnings Call TranscriptApr 18, 2024kr29.06 (-1.42%)Earnings
- Q4 2023 Hansa Biopharma AB Earnings Call TranscriptFeb 02, 2024kr31.32 (-7.88%)Earnings
- Hansa Biopharma AB Carlsquare Life Science Investor Day TranscriptDec 06, 2023
- Q3 2023 Hansa Biopharma AB Earnings Call TranscriptOct 26, 2023kr24.42 (-12.28%)Earnings
- Q2 2023 Hansa Biopharma AB Earnings Call TranscriptJul 20, 2023kr45.06 (+1.49%)Earnings
- Q1 2023 Hansa Biopharma AB Earnings Call TranscriptApr 20, 2023kr45.66 (-11.68%)Earnings
- Hansa Biopharma AB at TD Cowen Health Care Conference TranscriptMar 06, 2023
- Q4 2022 Hansa Biopharma AB Earnings Call TranscriptFeb 02, 2023kr53.5 (-12.94%)Earnings
- Nine months 2022 Hansa Biopharma AB Earnings Call TranscriptOct 20, 2022kr53.7 (-8.98%)Earnings
- Q2 2022 Hansa Biopharma AB Earnings Call TranscriptJul 19, 2022kr79 (+40.95%)Earnings
- Q1 2022 Hansa Biopharma AB Earnings Call TranscriptApr 21, 2022kr61.5 (+11.92%)Earnings
- Hansa Biopharma AB Erik Penser Bolagsdag Stockholm TranscriptMar 10, 2022
- Q4 2021 Hansa Biopharma AB Earnings Call TranscriptFeb 03, 2022kr63.8 (-15.09%)Earnings
- Hansa Biopharma AB Deep Dive: Gene Therapy Hosted by HC Andersen Capital TranscriptNov 05, 2021
- Hansa Biopharma AB Redeye Interview TranscriptOct 22, 2021
- Q3 2021 Hansa Biopharma AB Earnings Call TranscriptOct 21, 2021kr109.1 (+0.41%)Earnings
- Hansa Biopharma AB at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 15, 2021
- Q2 2021 Hansa Biopharma AB Earnings Call TranscriptJul 15, 2021kr114.2 (-17.19%)Earnings
- Hansa Biopharma AB Redeye Orphan Drugs Event - Corporate Call TranscriptApr 28, 2021
- Q1 2021 Hansa Biopharma AB Earnings Call TranscriptApr 22, 2021kr179.1 (+12.29%)Earnings
- Full Year 2020 Hansa Biopharma AB Earnings Call TranscriptFeb 04, 2021kr181.5 (+0.55%)Earnings
- Hansa Biopharma AB at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
- Hansa Biopharma AB Corporate Analyst Meeting TranscriptOct 29, 2020
- Hansa Biopharma AB at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 18, 2020
- Half Year 2020 Hansa Biopharma AB Earnings Call TranscriptJul 16, 2020kr252 (-2.55%)Earnings
- Hansa Biopharma AB (publ) - Special Call TranscriptJul 02, 2020
- Hansa Biopharma AB at UBS Global Healthcare Conference (Virtual) TranscriptMay 18, 2020
- Q1 2020 Hansa Biopharma AB Earnings Call TranscriptApr 28, 2020kr121.1 (+5.49%)Earnings
- Q4 2019 Hansa Biopharma AB Earnings Call TranscriptFeb 06, 2020kr70.15 (-5.39%)Earnings
- Hansa Biopharma AB (publ) - Special Call TranscriptDec 13, 2019
- Nine Months 2019 Hansa Biopharma AB Earnings Call TranscriptOct 31, 2019kr128.5 (-8.93%)Earnings
- Hansa Biopharma AB at Morgan Stanley Healthcare Conference TranscriptSep 10, 2019
- Q2 2019 Hansa Biopharma AB Earnings Call TranscriptJul 18, 2019kr172.9Earnings
- Hansa Biopharma AB at UBS Global Healthcare Conference TranscriptMay 20, 2019
- Q1 2019 Hansa Biopharma AB Earnings Call TranscriptApr 29, 2019Earnings
Hansa Biopharma AB Corporate Analyst Meeting Transcript
()-
Good afternoon, and welcome to the Hansa Biopharma Capital Markets Day. My name is Klaus Sindahl, and I'm Head of Investor Relations at Hansa Biopharma. I'm very pleased that Hansa Biopharma is hosting its third Capital Markets Day here in Copenhagen on the back of an eventful summer with many milestones achieved, milestones which essentially are transforming the company into a commercial stage biopharmaceutical company.
I'm also really excited about the program and the lineup of speakers we have this afternoon. The presentations will take us through very interesting aspects of Hansa Biopharma, both in terms of our recent progress, but also highlight opportunities outside of kidney transplantation in new areas such as gene therapy and autoimmunity. This also underpins that we have a very unique technology asset with very broad commercial opportunities also outside kidney transplantation.
I also wanted to introduce today's moderator, Rachel Curtis Gravesen. Many of you would know Rachel from a long
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)